GV has joined the investors in oncology treatment developer Relay Therapeutics, which has now raised $120m altogether.
US-based cancer therapy developer Relay Therapeutics closed a $63m series B round yesterday featuring GV, an early-stage investment vehicle for internet technology group Alphabet.
The round was led by investment firm BVF Partners and included Alexandria Venture Investments, a division of life science real estate developer Alexandria Real Estate Equities, as well as Third Rock Ventures, Casdin Capital, EcoR1 Capital and Section 32.
Relay Therapeutics is creating a drug discovery platform that relies on insights into protein motion, making it possible…